Jeff Jones
Stock Analyst at Oppenheimer
(0.89)
# 3,789
Out of 4,944 analysts
95
Total ratings
23.53%
Success rate
-15.76%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $9.59 | +452.66% | 10 | Aug 6, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $56 → $53 | $40.74 | +30.09% | 5 | Jun 27, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $18.05 | +143.83% | 3 | Jun 24, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $20 → $15 | $8.51 | +76.26% | 3 | May 29, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $11 → $10 | $0.96 | +943.84% | 8 | May 16, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $4.42 | +465.61% | 2 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $1.59 | +969.18% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $5.00 | +240.00% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $33.00 | +160.61% | 2 | May 8, 2025 | |
| EVH Evolent Health | Maintains: Outperform | $28 → $18 | $8.97 | +100.67% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.42 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $3.81 | +319.95% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 → $9 | $2.85 | +215.79% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.60 | +2,712.50% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $15.97 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.06 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28,800 | $8.90 | +323,495.51% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.47 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.55 | +867.74% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.67 | +11,014.40% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $3.04 | +36,084.21% | 2 | Nov 17, 2022 |
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $9.59
Upside: +452.66%
Kymera Therapeutics
Jun 27, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $40.74
Upside: +30.09%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $18.05
Upside: +143.83%
Y-mAbs Therapeutics
May 29, 2025
Maintains: Outperform
Price Target: $20 → $15
Current: $8.51
Upside: +76.26%
Chemomab Therapeutics
May 16, 2025
Maintains: Outperform
Price Target: $11 → $10
Current: $0.96
Upside: +943.84%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $4.42
Upside: +465.61%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $1.59
Upside: +969.18%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $5.00
Upside: +240.00%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $33.00
Upside: +160.61%
Evolent Health
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $8.97
Upside: +100.67%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $4.42
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.81
Upside: +319.95%
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.85
Upside: +215.79%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.60
Upside: +2,712.50%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $15.97
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.06
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $28,800
Current: $8.90
Upside: +323,495.51%
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $3.47
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.55
Upside: +867.74%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.67
Upside: +11,014.40%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $3.04
Upside: +36,084.21%